{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:36:01Z","timestamp":1734500161547,"version":"3.30.2"},"reference-count":0,"publisher":"Knowledge E DMCC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJN"],"abstract":"<jats:p>Background: This study was conducted to review the demographic and clinical characteristics, treatment protocols, and visual outcomes of patients with optic neuropathy.\r\nMethods: This historical cohort study analyzed the clinical features of 91 patients with optic neuropathy followed up for three years at a university hospital in Turkey.\r\nResults: Non-arteritic anterior ischemic optic neuropathy (NA-AION) was the most common group among the optic neuropathy subgroups (47.2%), and optic neuritis (ON) was the second most common group (38.5%). The mean age of symptom onset for NA-AION was 64.97 \u00b1 12.15 years, significantly higher than the mean age of onset for ON (40.28 \u00b1 15.52 years). Most of the patients with NA-AION had at least one systemic disease causing microangiopathy [51.1% had diabetes mellitus (DM), 33.3% had hypertension (HTN)]. Among the patients with ON, 51.4% were idiopathic, and 25.7% were multiple sclerosis (MS)-related ON cases. Patients with ischemic optic neuropathy (ION), ON, and traumatic optic neuropathy received pulse intravenous (IV) corticosteroids, and eleven patients with NA-AION received acetylsalicylic acid (ASA) therapy in addition to corticosteroids. There was a statistically significant increase in visual acuity in NA-AION and ON groups \u00a0(P = 0.019). It was observed that the cases of ON peaked in the winter months in Turkey.\r\nConclusion: In the differential diagnosis between NA-AION and idiopathic ON, the presence of one or more vascular systemic diseases and mean age may be the main factors. IV steroid treatment given to patients with NA-AION in the acute phase may significantly improve visual acuity.<\/jats:p>","DOI":"10.18502\/cjn.v21i3.11110","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T08:02:18Z","timestamp":1668412938000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical, demographic characteristics, and treatment protocols of optic neuropathies: Three-year follow-up experiences from a tertiary hospital  in Turkey"],"prefix":"10.18502","author":[{"given":"Burcu Taskiran","family":"Kandeger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Tok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"Tok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7770","published-online":{"date-parts":[[2022,11,13]]},"container-title":["Current Journal of Neurology"],"original-title":[],"link":[{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/download\/11110\/10521","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/download\/11110\/10521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T17:16:08Z","timestamp":1734455768000},"score":1,"resource":{"primary":{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/view\/11110"},"secondary":[{"URL":"https:\/\/cjn.tums.ac.ir\/article_40038.html","label":"UNIVERSITY"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/CJN\/article\/view\/11110","label":"PUBLISHER"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,13]]},"references-count":0,"URL":"https:\/\/doi.org\/10.18502\/cjn.v21i3.11110","relation":{},"ISSN":["2717-011X"],"issn-type":[{"type":"electronic","value":"2717-011X"}],"subject":[],"published":{"date-parts":[[2022,11,13]]}}}